Potential use of P-32 ophthalmic applicator: Monte Carlo simulations for design and dosimetry

Yang Kyun Park, Sung Joon Ye, Il Han Kim, Won Ryang Wee, Mee Kum Kim, Hyon Soo Han, Kwang Jae Son, Ul Jae Park

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Postoperative β-irradiation after pterygium excision has been considered a valuable therapeutic procedure to reduce the recurrence rate. Recently, it was reported that β-irradiation also substantially reduced the risk of surgical failure after glaucoma surgery. Pure β-irradiation using a Sr90 Y applicator has been almost exclusively used for this purpose. As an alternative to Sr90 Y β-irradiation, we propose treatment with betas of a P32 source. While P32 has a lower maximum energy (1.71 MeV) than Sr90 Y (2.27 MeV), it has an average energy comparable to that of Sr90 Y. Furthermore, it can be produced easily in a nuclear reactor by neutron activation and is considered a less hazardous material. Monte Carlo simulations for the dosimetry of proposed P32 applicators were performed using the MCNP5 code. The structure and dimension of the P32 applicators were based on those of the Sr90 Y applicators currently available, while medical plastic encapsulation and liquid source were chosen to enhance β-dose to the surface of the conjunctiva. The P32 applicator showed that the surface dose distribution (up to 0.75 mm depth) is very similar to that of Sr90 Y. However, beyond 0.75 mm depth, the P32 doses decrease with depths more rapidly than Sr90 Y doses. In order to achieve the same surface dose rate, the required P32 activity is about three times that for a Sr90 Y applicator. We conclude that the proposed P32 applicator can deliver therapeutic doses to the target lesion while sparing the lens better than the Sr90 Y applicator. The P32 activity required to deliver therapeutic doses can be produced in a 30 MW reactor available at the Korea Atomic Energy Research Institute.

Original languageEnglish (US)
Pages (from-to)1854-1858
Number of pages5
JournalMedical Physics
Volume35
Issue number5
DOIs
StatePublished - Jan 1 2008

Fingerprint

Nuclear Reactors
Nuclear Energy
Pterygium
Hazardous Substances
Conjunctiva
Neutrons
Korea
Glaucoma
Lenses
Plastics
Therapeutics
Recurrence

Keywords

  • P applicator
  • Glaucoma
  • Monte Carlo simulations
  • Pterygium
  • Reactor

ASJC Scopus subject areas

  • Biophysics
  • Radiology Nuclear Medicine and imaging

Cite this

Park, Y. K., Ye, S. J., Kim, I. H., Wee, W. R., Kim, M. K., Han, H. S., ... Park, U. J. (2008). Potential use of P-32 ophthalmic applicator: Monte Carlo simulations for design and dosimetry. Medical Physics, 35(5), 1854-1858. https://doi.org/10.1118/1.2896076

Potential use of P-32 ophthalmic applicator : Monte Carlo simulations for design and dosimetry. / Park, Yang Kyun; Ye, Sung Joon; Kim, Il Han; Wee, Won Ryang; Kim, Mee Kum; Han, Hyon Soo; Son, Kwang Jae; Park, Ul Jae.

In: Medical Physics, Vol. 35, No. 5, 01.01.2008, p. 1854-1858.

Research output: Contribution to journalArticle

Park, YK, Ye, SJ, Kim, IH, Wee, WR, Kim, MK, Han, HS, Son, KJ & Park, UJ 2008, 'Potential use of P-32 ophthalmic applicator: Monte Carlo simulations for design and dosimetry', Medical Physics, vol. 35, no. 5, pp. 1854-1858. https://doi.org/10.1118/1.2896076
Park, Yang Kyun ; Ye, Sung Joon ; Kim, Il Han ; Wee, Won Ryang ; Kim, Mee Kum ; Han, Hyon Soo ; Son, Kwang Jae ; Park, Ul Jae. / Potential use of P-32 ophthalmic applicator : Monte Carlo simulations for design and dosimetry. In: Medical Physics. 2008 ; Vol. 35, No. 5. pp. 1854-1858.
@article{d60bc04d1c9d48d0a50de62b20cd0439,
title = "Potential use of P-32 ophthalmic applicator: Monte Carlo simulations for design and dosimetry",
abstract = "Postoperative β-irradiation after pterygium excision has been considered a valuable therapeutic procedure to reduce the recurrence rate. Recently, it was reported that β-irradiation also substantially reduced the risk of surgical failure after glaucoma surgery. Pure β-irradiation using a Sr90 Y applicator has been almost exclusively used for this purpose. As an alternative to Sr90 Y β-irradiation, we propose treatment with betas of a P32 source. While P32 has a lower maximum energy (1.71 MeV) than Sr90 Y (2.27 MeV), it has an average energy comparable to that of Sr90 Y. Furthermore, it can be produced easily in a nuclear reactor by neutron activation and is considered a less hazardous material. Monte Carlo simulations for the dosimetry of proposed P32 applicators were performed using the MCNP5 code. The structure and dimension of the P32 applicators were based on those of the Sr90 Y applicators currently available, while medical plastic encapsulation and liquid source were chosen to enhance β-dose to the surface of the conjunctiva. The P32 applicator showed that the surface dose distribution (up to 0.75 mm depth) is very similar to that of Sr90 Y. However, beyond 0.75 mm depth, the P32 doses decrease with depths more rapidly than Sr90 Y doses. In order to achieve the same surface dose rate, the required P32 activity is about three times that for a Sr90 Y applicator. We conclude that the proposed P32 applicator can deliver therapeutic doses to the target lesion while sparing the lens better than the Sr90 Y applicator. The P32 activity required to deliver therapeutic doses can be produced in a 30 MW reactor available at the Korea Atomic Energy Research Institute.",
keywords = "P applicator, Glaucoma, Monte Carlo simulations, Pterygium, Reactor",
author = "Park, {Yang Kyun} and Ye, {Sung Joon} and Kim, {Il Han} and Wee, {Won Ryang} and Kim, {Mee Kum} and Han, {Hyon Soo} and Son, {Kwang Jae} and Park, {Ul Jae}",
year = "2008",
month = "1",
day = "1",
doi = "10.1118/1.2896076",
language = "English (US)",
volume = "35",
pages = "1854--1858",
journal = "Medical Physics",
issn = "0094-2405",
publisher = "AAPM - American Association of Physicists in Medicine",
number = "5",

}

TY - JOUR

T1 - Potential use of P-32 ophthalmic applicator

T2 - Monte Carlo simulations for design and dosimetry

AU - Park, Yang Kyun

AU - Ye, Sung Joon

AU - Kim, Il Han

AU - Wee, Won Ryang

AU - Kim, Mee Kum

AU - Han, Hyon Soo

AU - Son, Kwang Jae

AU - Park, Ul Jae

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Postoperative β-irradiation after pterygium excision has been considered a valuable therapeutic procedure to reduce the recurrence rate. Recently, it was reported that β-irradiation also substantially reduced the risk of surgical failure after glaucoma surgery. Pure β-irradiation using a Sr90 Y applicator has been almost exclusively used for this purpose. As an alternative to Sr90 Y β-irradiation, we propose treatment with betas of a P32 source. While P32 has a lower maximum energy (1.71 MeV) than Sr90 Y (2.27 MeV), it has an average energy comparable to that of Sr90 Y. Furthermore, it can be produced easily in a nuclear reactor by neutron activation and is considered a less hazardous material. Monte Carlo simulations for the dosimetry of proposed P32 applicators were performed using the MCNP5 code. The structure and dimension of the P32 applicators were based on those of the Sr90 Y applicators currently available, while medical plastic encapsulation and liquid source were chosen to enhance β-dose to the surface of the conjunctiva. The P32 applicator showed that the surface dose distribution (up to 0.75 mm depth) is very similar to that of Sr90 Y. However, beyond 0.75 mm depth, the P32 doses decrease with depths more rapidly than Sr90 Y doses. In order to achieve the same surface dose rate, the required P32 activity is about three times that for a Sr90 Y applicator. We conclude that the proposed P32 applicator can deliver therapeutic doses to the target lesion while sparing the lens better than the Sr90 Y applicator. The P32 activity required to deliver therapeutic doses can be produced in a 30 MW reactor available at the Korea Atomic Energy Research Institute.

AB - Postoperative β-irradiation after pterygium excision has been considered a valuable therapeutic procedure to reduce the recurrence rate. Recently, it was reported that β-irradiation also substantially reduced the risk of surgical failure after glaucoma surgery. Pure β-irradiation using a Sr90 Y applicator has been almost exclusively used for this purpose. As an alternative to Sr90 Y β-irradiation, we propose treatment with betas of a P32 source. While P32 has a lower maximum energy (1.71 MeV) than Sr90 Y (2.27 MeV), it has an average energy comparable to that of Sr90 Y. Furthermore, it can be produced easily in a nuclear reactor by neutron activation and is considered a less hazardous material. Monte Carlo simulations for the dosimetry of proposed P32 applicators were performed using the MCNP5 code. The structure and dimension of the P32 applicators were based on those of the Sr90 Y applicators currently available, while medical plastic encapsulation and liquid source were chosen to enhance β-dose to the surface of the conjunctiva. The P32 applicator showed that the surface dose distribution (up to 0.75 mm depth) is very similar to that of Sr90 Y. However, beyond 0.75 mm depth, the P32 doses decrease with depths more rapidly than Sr90 Y doses. In order to achieve the same surface dose rate, the required P32 activity is about three times that for a Sr90 Y applicator. We conclude that the proposed P32 applicator can deliver therapeutic doses to the target lesion while sparing the lens better than the Sr90 Y applicator. The P32 activity required to deliver therapeutic doses can be produced in a 30 MW reactor available at the Korea Atomic Energy Research Institute.

KW - P applicator

KW - Glaucoma

KW - Monte Carlo simulations

KW - Pterygium

KW - Reactor

UR - http://www.scopus.com/inward/record.url?scp=42949085131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42949085131&partnerID=8YFLogxK

U2 - 10.1118/1.2896076

DO - 10.1118/1.2896076

M3 - Article

C2 - 18561660

AN - SCOPUS:42949085131

VL - 35

SP - 1854

EP - 1858

JO - Medical Physics

JF - Medical Physics

SN - 0094-2405

IS - 5

ER -